Mutations in the human MMAA gene cause the metabolic disorder cblA-type methylmalonic aciduria (MMA), although knowledge of the mechanism of dysfunction remains lacking. MMAA regulates the incorporation of the cofactor adenosylcobalamin (AdoCbl), generated from the MMAB adenosyltransferase, into the destination enzyme methylmalonyl-CoA mutase (MUT). This function of MMAA depends on its GTPase activity, which is stimulated by an interaction with MUT.
INTRODUCTION
In humans, vitamin B 12 (cobalamin, Cbl) is modified through various steps to function as a cofactor for two enzymes, methionine synthase in the cytosol, which utilizes methylcobalamin, and methylmalonyl-CoA mutase (MUT, MIM# 609058, EC 5.4.99.2) in the mitochondria, requiring adenosylcobalamin (AdoCbl). The distinct modifications required to produce the correct Cbl cofactor forms and the different subcellular locations of the two enzymes have led to the emergence of a finely tuned pathway ensuring correct uptake, processing and delivery of Cbl to these destination enzymes. MUT is responsible for the rearrangement of methylmalonyl-CoA to succinyl-CoA, which enters the tricarboxylic acid cycle. This reaction is a main step in propionate catabolism, as it funnels metabolites from the breakdown of branched-chain amino acids, odd-chain fatty acids, and the side chain of cholesterol into the tricarboxylic acid cycle (Fowler, Leonard, & Baumgartner, 2008) . In the multi-player process of AdoCbl delivery to MUT, the protein MMAB (Dobson et al., 2002a; Leal, Olteanu, Banerjee, & Bobik, 2004) , produces AdoCbl in an ATP-dependent transfer, whereas MMAA (MIM# 607481, EC:2.7.-.-.) is responsible for proper AdoCbl incorporation into MUT through a GTP-dependent interaction (Padovani, & Banerjee, 2009; Padovani, Labunska, & Banerjee, 2006) .
MMAA is a small G-protein belonging to the G3E family of P-loop GTPases (Leipe, Wolf, Koonin, & Aravind, 2002) . It consists of a central G-domain, which encompasses the four GTPase signature motifs (Switch I, Switch II, P-loop, and base specificity loop), flanked by an Nterminal extension and a C-terminal dimerization arm (Froese et al., 2010) . MMAA is highly conserved from bacteria to human, and studies in the Methylobacterium extorquens (M. ext.) ortholog MeaB, which has a similar monomeric structure, have provided many insights into the function of MMAA (Hubbard et al., 2007) . Interaction between MMAA and MUT was first shown using their M. ext. orthologs MeaB and MCM, respectively (Korotkova, & Lidstrom, 2004; . Furthermore, these homologs have been used to show stimulation of MeaB GTPase activity upon MCM binding, the importance of the GTPase activity of MeaB to gate AdoCbl incorporation into MCM by blocking unproductive conformations and the ejection of oxidized cobalamin from MCM by MeaB , 2009 .
Nevertheless, important differences between MMAA and MeaB, as well as MUT and MCM, remain. For example, although MMAA and MeaB protomers have a similar structure, their homodimeric structures show marked differences (Froese et al., 2010) . Likewise, although MUT functions as a homodimer of two catalytic subunits, MCM is heterodimeric with only one catalytic subunit (Froese et al., 2010) . These differences suggest that human MMAA and MUT may interact in a manner distinct from their bacterial counterparts. Indeed, investigations into the oligomeric assembly and ligand requirements for the interaction of the human proteins show they are different from that of MeaB and MCM (Froese et al., 2010; Hubbard et al., 2007) . Therefore, although much can be inferred about the function of MMAA from its bacterial homolog, there is still much to discover.
A disturbed function of MMAA caused by autosomal recessive mutations in the MMAA gene results in methylmalonic aciduria (MMA) of the cblA-type (OMIM: 251100) (Dobson et al., 2002b) . Clinically, disease presentation is almost identical to that of MUT deficiency (MMA mut-type; OMIM: 251000), although usually somewhat milder (Hörster et al., 2007) . For each, symptoms vary widely, presenting in neonates through to adulthood with a range of symptoms, including recurrent vomiting, failure to thrive, progressive renal dysfunction, and neurologic complications. If untreated, metabolic crisis can result in lethal multi-organ failure, underlining the importance of improving the knowledge about disease pathology (Hörster et al., 2007; Matsui, Mahoney, & Rosenberg, 1983) . To date, about 140 cblA patients harboring 41 different mutations in MMAA have been published (Ampola, Mahoney, Nakamura, & Tanaka, 1975; Dempsey-Nunez et al., 2012; Dobson et al., 2002b; Gravel, Mahoney, Ruddle, and Rosenberg, 1975; Hörster et al., 2007; Lerner-Ellis et al., 2004; Martínez et al., 2005; Matsui et al., 1983; Merinero et al., 2008; Nizon et al., 2013; Rosenberg, Lilljeqvist, and Hsia, 1968; Vatanavicharn et al., 2012; Yang et al., 2004) . The nonsense mutation c.433C>T (p.Arg145*), resulting in a premature stop-codon, accounts for the majority of pathogenic alleles (Lerner-Ellis et al., 2004) . Biochemical analysis of the MMAA patient missense mutation p.Gly188Arg demonstrated impaired complex formation with MUT as its only discernible defect (Froese et al., 2010) , highlighting the importance of this interaction for B 12 pathway function, and suggesting that other mutations may result in a similar dysfunction.
In this study, we present data from 67 unpublished patients with cblA-type MMA, from which 19 novel mutations in the MMAA gene were identified. Analysis of all known MMAA missense mutations to date indicate that about one-third confer instability to the protein and the rest show a markedly reduced ability to functionally interact with MUT, which further affects the transfer of AdoCbl from MMAB to MUT. This work suggests that it is not loss of MMAA activity that causes disease, but rather lost interaction with MUT.
MATERIALS AND METHODS

Genotyping
Skin fibroblasts or blood samples were taken from patients with biochemical and clinical evidence of cblA-type MMA, referred to our institution for diagnostic purposes. The study has been approved by the ethics commission of the Canton of Zurich, Switzerland (application no. 2014-0211). Genomic DNA (gDNA) extraction from cultured patient fibroblasts was performed using the QIAamp DNA Mini Kit and from EDTA blood using the DNEasy Blood and Tissue Kit (Qiagen, Venlo, The Netherlands). RNA extraction was performed using the RNeasy Mini Kit (Qiagen). Mutations were identified by amplification of exons by PCR from gDNA using flanking intronic primers and sequencing using the ABI BigDye method (Applied Biosystems, Thermo Fisher Scientific, CA). The nomenclature of the mutations is based on the cDNA sequence NM 172250.2. Nucleotide numbering uses +1 as the A of the ATG translation initiation codon in the reference sequence, with the initiation codon as codon 1. All of the variants in Table 1 were submitted to the freely accessible NCBI ClinVar Database http://www.ncbi.nlm.nih.gov/clinvar/ using the standard HGVS nomenclature.
Propionate incorporation assay
Patient fibroblasts were cultured in Earle's minimal essential medium (Gibco, Carlsbad, CA) supplemented with 10% fetal calf serum (Gibco), 2 mM L-glutamine (Gibco), and antibiotics (GE Healthcare, Little Chalfont, UK), as described earlier (Suormala et al., 2004) . Incorporation of 14 C-propionate was assayed in cultured skin fibroblasts grown in the presence or absence of hydroxycobalamin (OH-Cbl; 1 or 10 mg/l) and was performed as described previously (Suormala et al., 2004 ) by a slightly modified method of Willard, Ambani, Hart, Mahoney, and Rosenberg (1976) .
Cloning
For expression in Escherichia coli, we used previously described constructs of MMAA, encompassing amino acids 73-424 in the pNIC28- Bsa4 vector, and MUT, encompassing amino acids 12-750 in the pNIC-CTHF vector (Froese et al., 2010) , resulting in constructs without the mitochondrial localization sequence. For MMAB expression, a DNA fragment encoding N-terminally truncated MMAB (amino acids 51-250, no mitochondrial localization sequence) was subcloned from IMAGE clone 3938643 into the pNIC28-Bsa4 vector. For expression in HEK293 cells, a DNA fragment encoding full-length MMAA (IMAGE clone 40017263) was subcloned into the vector pCDNA3-C-Flag-LIC using LIC cloning. Site-directed mutagenesis was carried out using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) as described in the manufacturer's instructions, using forward and reverse primers (Microsynth, Balgach, Switzerland) and confirmed by Sanger sequencing. All primers are available upon request.
Bacterial expression and purification
Wild-type (wt) and mutant MMAA, as well as MUT and MMAB, were expressed in E. coli and purified by affinity (Ni-NTA; Qiagen) and size-exclusion (Superdex 200; GE Healthcare) chromatography as described in Froese et al. (2010) . Small-scale purification of wt MMAA and all mutants was performed as described in Forny, Froese, Suormala, Yue, and Baumgartner (2014) . For large-scale purification, cells were grown in a total of 12 l, then harvested by centrifugation at 5,000×g for 10 min and lysed with a Badelin Sonoplus HD2070
homogenizer. Insoluble material was clarified by centrifugation at 5,000×g and the supernatant purified by affinity (Ni-NTA; Qiagen) and size-exclusion (Superdex 200; GE Healthcare) chromatography as described in Froese et al. (2010) .
Transfection and expression in HEK293 cells
HEK293 cells were transiently transfected with pCDNA3-C-Flag-LIC-MMAA wt and mutant constructs using electroporation (Baumgartner et al., 2001 ) and grown in Dulbecco's Modified Eagle Medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and antibiotics (GE Healthcare), as previously described (Suormala et al., 2004) . Cells were harvested by trypsinization 48 hr after electroporation, washed twice with HBSS (Gibco) and either frozen at −20°C or processed directly.
Immunoprecipitation and immunoblotting
Cell lysis was performed on fresh or frozen pellets resuspended in Fluorescence data were fit in GraphPad Prism (v6.07; GraphPad Software, Inc., San Diego, CA, USA).
Kinetics of MMAA GTP hydrolysis
Intrinsic GTPase activity of wt MMAA and mutants ( of Michelis-Menten kinetics was performed using GraphPad Prism (v6.07; GraphPad Software, Inc.) as previously described (Froese et al., 2010) .
Differential scanning fluorimetry
Purified mutant and wt MMAA proteins were diluted to 0.1 mg/ml in buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 5% glycerol) with 1:1,000 Sypro Orange (Invitrogen, Carlsbad, CA) and 25 M MgCl 2 (Sigma-Aldrich) and run in the apo-state or with pre-incubation of 0-2,000 M GDP (Sigma-Aldrich) or 0-5,000 M GMPPNP (SigmaAldrich) on a LightCycler R 480 machine (Roche, Basel, Switzerland).
Shifts in melting temperature (ΔT m ), final graphs and the AC 50 for each protein-ligand pair were calculated using GraphPad Prism (v6.07;
GraphPad Software, Inc.) software.
Size-exclusion chromatography
Analytical gel filtration was performed using a Superdex 200
HiLoad 10/30 column (GE Healthcare) pre-equilibrated with buffer containing 100 mM HEPES pH7.5, 300 mM KCl and 5% glycerol. Samples were prepared in the same buffer with 250 M MgCl 2 (SigmaAldrich) and 100 M GMPPNP (Sigma-Aldrich) added. Calibration of the column was performed using carbonic anhydrase (29 kDa), bovine serum albumin (66 kDa), alcohol dehydrogenase (150 kDa), and apo-ferritin (443 kDa) (Sigma-Aldrich) as MW-standards.
UV-visible spectroscopy
The release of AdoCbl was monitored by adding ATP (5-1,750 M)
to holo-MMAB (60 M bound AdoCbl) in buffer containing 100 mM HEPES pH 8.0, 300 mM KCl, 10 mM MgCl 2 , and 5% glycerol. After mixing, spectral curves were recorded from 300 to 700 nm and cofactor release was monitored at 525 nm. The release of AdoCbl from holo-MMAB was also measured in the presence of MUT (60 M), wt MMAA (60 M), or MMAA mutants (60 M) and in the presence of GTP, GDP, and GMPPNP (0.5 mM; Sigma-Aldrich).
RESULTS
Clinical features and mutation analysis of patients with cblA-type MMA
We present data from 67 previously unpublished cblA-type patients, listed in Table 1 and including the sex, age of onset, propionate incorporation profiles, and mutations found in these individuals. In this patient cohort, we found 34 different mutations in the MMAA gene: 11 missense mutations, 10 frameshifts, eight nonsense mutations, four splicesite defects, and one deletion. Of these, 19 represented novel mutations (in bold in Table 1 ). Of those mutations identified in more than one individual the most frequent was c.433C>T (p.Arg145*), identified in 25 alleles, accounting for 19% of pathogenic alleles. This was followed by c.592_595delACTG (p.Thr198Serfs*6), found in 19 alleles (14% of pathogenic alleles). The c.586C>T (p.Arg196*) mutation was identified in 15 alleles (11% of pathogenic alleles) and c.1075C>T
(p.Arg359*) was reported in 10 alleles (7%). Therefore, the proportion of nonsense mutations was high, accounting for 78% of mutated alleles.
Missense mutations occurred at a frequency of 16%, while the remaining mutation types were more rare. For 41 patients, information about the age of onset was available. Eight patients presented with a later onset of disease (>1 year) and 33 with an earlier onset of disease (<1 year, among them nine patients with neonatal onset). The latest age of onset in this patient group was 6.5 years. Forty-seven of the 49 patient fibroblasts (not patient's No. 5 and 50), which we were able to obtain, showed response to OHCbl supplementation in the propionate fixation assay (+OHCbl/−OHCbl> 1.5). This was in line with similar propionate incorporation results from other publications (Lerner-Ellis et al., 2004) as well as the noted clinical response of cblA-type patients to vitamin B 12 therapy (Hörster et al., 2007; Matsui et al., 1983) . No direct correlation could be made between the age of disease onset and the amount or ratio of propionate incorporation, nor between the age of disease onset and mutation type (data not shown).
One-third of MMAA missense mutations confer protein instability
Missense mutations, although the minority, are important in understanding the underlying biochemical mechanisms in dysfunctional MMAA. Therefore, we performed further studies of the defects conferred by all 22 known MMAA missense mutations, including the nine novel missense mutations described here.
Missense mutations have been described in the homozygous state, or in combination with a truncating allele, in 28 separate cblA-type patients (Supp . Table S1 ) and were localized across the entire polypeptide (Fig. 1A) . Few mutations were found in the N-terminal extension (n = 2) and the C-terminal dimerization arm (n = 3), whereas most occurred within the central G-domain (n = 17) (Fig. 1A) . proteins showed moderately disturbed expression levels (10%-60% wt), whereas p.Gly192Asp and p.Thr243Asn had closer to wt levels. For E. coli expression, mutant protein stability was assessed following single step affinity purification (Fig. 1C) . By this method, wt MMAA retained high protein recovery from the affinity eluant (Fig. 1C , lane E) compared with the total cellular lysate (Fig. 1C, (Fig. 1C) . Therefore, in total, seven out of 22 of MMAA missense mutations confer instability to the protein, agreeing with predictions from the FoldX server (http://foldxsuite.crg.eu/) that these mutations destabilize the structure (∆∆G between 3.48 and 11.15 kcal/mol). The 15 remaining mutant proteins could be visualized by Coomassie staining of the SDS gel, and thus were considered to be more stable. These 15 mutants were bacterially expressed in large scale and purified by affinity and size-exclusion chromatography for further investigation of their biochemical properties.
To quantify more subtle changes to stability, the thermolability of MMAA mutants from large-scale purification (n = 15) was determined using differential scanning fluorimetry (DSF). This method monitors the heat-induced unfolding of proteins in the presence of a fluorescent dye in order to measure the melting temperature (T m ) of the purified protein (Niesen, Berglund, & Vedadi, 2007) . The T m values of thirteen mutant proteins exhibited thermal stability similar to that of wt-protein (having ΔT m values between −2.3°C and +2.0°C
of the wt value of 48.5°C; Fig. 1D and Supp. Table S2 ). Although some mutants show a slight increase in thermal stability compared to wt-protein these values (+0.8-2.0°C) are just outside the range of assay variability and it is unlikely that these mutants have a stability advantage compared to wt-protein in the cell. Two mutants had significantly decreased thermal stability, p.Arg98Gly exhibited a ΔT m = −3.0°C, whereas p.Asp292Val reached a ΔT m = −4.0°C (Fig. 1D ).
GTP binding to MMAA is only reduced in a mutation located in the base-specificity loop
The chaperone/gating function of MMAA depends on GTP-binding and GTPase activity. To assess the influence of MMAA missense mutations on the ability of MMAA to bind GDP and GMPPNP (non-hydrolysable analogue of GTP), we further utilized DSF to determine ligand-induced T m changes. Incubation of wt MMAA with increasing concentrations of GDP or GMPPNP resulted in large increases in T m of up to 6.0°C for GMPPNP ( Fig. 2A ) and 9.0°C for GDP (Fig. 2B) . The binding of GTP to MMAA was confirmed by using fluorescently labeled mant-GTP (Supp. 
Measurement of the T m values of all purified mutant proteins
to determine stabilization by GDP/GMPPNP binding revealed only one mutation, p.Asp292Val, located in the base-specificity loop, a motif in the G-domain that is directly involved in nucleotide binding (Supp. Fig. S2 ), that showed a strongly reduced T m compared with wt protein in the presence of nucleotides ( Fig. 2A and B and Supp. Table S2 ). This mutant showed a maximum T m increase of 1.8°C for GDP and 1.6°C for GMPPNP, indicating loss of protein stabilization due to severely reduced nucleotide binding ( Fig. 2C and Supp. Table   S2 ). The rest of the mutant proteins showed T m changes (with vs. without ligand) comparable to wt protein (GDP: 7.8-9.5°C, GMPPNP: 4.6-6.8°C; Supp. Table S2 ). Using the curves in Figure 2A and B, we further determined the activation constant (AC 50 ), a surrogate marker of the dissociation constant (K d ), for wt MMAA protein and each mutant for both nucleotides (Supp. Table S2 ). The AC 50 for GDP was much lower than that of GMPPNP for wt MMAA (Supp. To further evaluate the contribution of the base-specificity loop to nucleotide binding, we generated a double mutant (p.Lys290Ala+
Asp292Ala) following identification of p.Lys290 as a residue directly involved in nucleotide binding in the crystal structures of both human MMAA and its bacterial ortholog MeaB (Supp. Nucleotide binding evaluated using mant-GTP also confirmed impairment (p.Asp292Val) and loss (p.Lys290Ala+Asp292Ala) of GTP binding for the mutations (Supp. Fig. S1 ). Therefore, as predicted from 
GTPase activity stimulation by MUT is strongly impaired in all MMAA mutants
MMAA is a G-protein belonging to the G3E family of P-loop GTPases (Leipe et al., 2002) . When assessed for the ability to cleave GTP into GDP and Pi, wt MMAA showed very low intrinsic GTPase activity, which could be highly stimulated by pre-incubation with MUT, consistent with published results (Froese et al., 2010) (Fig. 3A) . As expected, incubation of MUT alone resulted in no detectable GTPase activity (Fig. 3A) . Since most missense mutations are found in the domain responsible for GTPase activity (G-domain, Fig. 1A ), we compared the activity of each mutant protein alone at 1,000 M GTP to that of wt enzyme. Surprisingly, all proteins harbouring patient missense mutations had similar intrinsic GTPase activity to wt-levels (68%-108% compared with wt-protein), with the exception of p.Arg98Gly, which substantially decreased activity (45% compared with wt-protein) (Fig. 3B) . The base-specificity loop double mutant p.Lys290Ala + Asp292Ala, which shows strongly reduced nucleotide binding, had 29% wt activity.
Nevertheless, all mutants showed activity levels substantially, and significantly, above those in the assay negative control (without MMAA protein), or with the double mutant, and similar to that of the wt enzyme.
The GTPase activity of wt MMAA protein after pre-incubation with MUT was strongly stimulated by an order of magnitude (catalytic efficiency k cat /K m = 0.123 min −1 /pmol without; 4.81 min −1 /pmol with MUT stimulation), consistent with previous observations (Froese et al., 2010) and permitting easy calculation of kinetic values. This GTPase activity stimulation by MUT was strongly reduced in all 15 mutants, by threefold to 150-fold compared with wt MMAA (Fig. 3C and Supp. 
Physical interaction with MUT is abrogated in most MMAA mutants
To assess physical interaction between MMAA and MUT, analytical size-exclusion chromatography was employed. MMAA migrated with an apparent molecular weight (MW) of 80 kDa, and MUT with a MW of 215 kDa, consistent with homodimer formation in each case ( Fig. 4A and Supp. Fig. S3 ). When wt MMAA and MUT were preincubated in the presence of GMPPNP and Mg 2+ , an additional complex peak, with an apparent MW of 685 kDa, was identified ( Fig. 4A and Supp. Fig. S3 ). This complex peak is consistent with the presence of both proteins, as described previously (Froese et al., 2010) . Interestingly, complex formation requires MMAA to be pre-bound to GMPPNP in the presence of Mg 2+ for its formation, as in the absence of these components, no complex peak was observed (unpublished observations). All 15 purified MMAA mutant proteins were tested by analytical size-exclusion chromatography for complex formation with MUT (Supp. Fig. S4 and Fig. 4A ). Six mutants (p.Gly192Asp, p.Arg196Gln, p.Glu250Lys, p.Gly274Ser, p.Lys276Glu, p.Arg359Gly) retained the ability to physically interact with MUT, albeit to a lesser extent than wt (Supp. Fig. S4 ), whereas the other nine, including the four mutations (p.Arg98Gly, p.Gly188Arg, p.Gly218Glu, p.Thr243Asn) with the lowest GTPase activity stimulation, produced no detectable interaction peak.
Information regarding each mutant protein's ability to interact with MUT is provided in Supp. Table S3 and for visualization examples of a mutant protein which retains the capacity to interact (p.Gly192Asp) and one that did not (p.Thr243Asn) are depicted in Figure 4A . Interaction between wt MMAA and MUT was confirmed in vivo by coimmunoprecipitating flag-tagged MMAA and endogenous MUT from MMAA transfected HEK293 cells (Fig. 4B) . Importantly, this interaction was also dependent on the presence of Mg 2+ and GMPPNP in the lysis buffer (Supp. Fig. S5 ), corresponding to our in vitro findings. Under these conditions, a band corresponding to MUT was detected in cells expressing flag-tagged wt MMAA and, to a lesser extent, p.Gly192Asp-MMAA, whereas no MUT protein was detected after immunoprecipitation with p.Thr243Asn-MMAA (Fig. 4B) . These results were in accordance with our in vitro findings.
Release of AdoCbl from MMAB is affected in MMAA mutants unable to bind MUT
In (Fig. 5) . Interestingly, in mutants unable to physically interact with 
DISCUSSION
As a basis for this comprehensive study on mechanisms associated with MMAA missense mutations we characterised 67 previously unpublished cblA-type MMA patients, including 19 novel mutations.
We found no direct correlation between age of onset and mutation type, suggesting other factors, such as intercurrent illness, diet or other hereditary components, may contribute to disease onset. In this cohort, c.433C>T (p.Arg145*) was the most frequently identified pathogenic allele. This mutation was also the most frequently found mutation in previous studies (Dempsey-Nunez et al., 2012; Lerner-Ellis et al., 2004) . As in those studies, c.592_595delACTG (p.Thr198Serfs*6) was the second most prevalent mutation found here. This confirms the prominence of truncating type mutations and suggests that the complete absence of MMAA protein, via protein truncation, is the cause of disease in most patients with cblA-type MMA. On the other hand, missense mutations occurred only at a frequency of 16%. This is in contrast to other metabolic diseases (Caldovic, Abdikarim, Narain, Tuchman, & Morizono, 2015; Mitchell, Trakadis, & Scriver, 2011) and to other proteins in the vitamin B 12 pathway (Forny et al., 2016) , where missense mutations represent the majority of identified mutations. We found it of particular interest to determine the mechanism by which single amino acid changes in MMAA lead to malfunction and disease.
To this end, we analyzed biochemically all 22 known missense mutations, including nine novel mutations identified here. We have carried out thermostability, ligand binding, GTPase activity and protein interaction assays that probe the various properties of MMAA, constituting the largest biochemical analysis of MMAA mutations so far and found a number of mechanisms associated with missense mutations. These results are summarized in Table 2 . 
Investigation of nucleotide binding showed that wt MMAA and all mutants had a higher affinity for GDP than GMPPNP. This is in contrast to bacterial MeaB, which was shown to bind both nucleotide forms with similar affinity , and is reminiscent of the majority of eukaryotic small GTPases which prefer GDP binding (Cherfils, & Zeghouf, 2011) . For example, several studies analysing GTPases of the Ras family, which serve as prototypes for the hydrolysis reaction of small G proteins, were shown to bind preferably to GDP (White et al., 2016) . However, in the cellular environment, where the concentration of GTP is higher than GDP, these proteins are found predominantly in the GTP-bound form (Cox, Fesik, Kimmelman, Luo, & Der, 2014) . Unsurprisingly, only those mutations found within the base-specificity loop of MMAA affected GDP/GMPPNP binding.
We found only one mutant (Arg98Gly), located in the N-terminal extension, to cause disruption of the low basal GTPase activity found in wt protein. Since this mutation also caused protein thermolability, perhaps incomplete or improper folding affected its activity. Although intrinsic GTPase activity of wt MMAA was shown to be very low, it could be highly stimulated by pre-incubation with apo-MUT (Froese et al., 2010; . However, for all mutant proteins, this stimulation was strongly inhibited. We investigated the physical interaction of the two proteins in vitro and in vivo to investigate if loss of interaction is the universal cause of impaired GTPase stimulation. Analysis of the physical interaction of the two proteins in vitro and in vivo revealed six mutants that were still able to physically bind to MUT. Interestingly, four of those mutations (Lys276Glu, Glu250Lys, Gly274Ser, Arg359Gly) accounted for the highest catalytic efficiency (11.7%-29.5% of wt-catalytic efficiency) of all the mutant proteins, suggesting that the ability to maintain physical interaction, at least partly, correlated with activity stimulation. The fact that some mutations resulted in abrogation of the physical interaction with MUT, while others left it intact, suggests that a number of mechanisms leading to the loss of functional interaction may be incorporated by different mutations. For example, some MMAA residues might be involved in the full creation of an active site during MUT stimulation, reminiscent of the Arg-finger in Ras-family members which stabilizes the transition state during GTP hydrolysis (Scheffzek et al., 1997) . In this scenario, modification of the active site by introducing amino acid changes might is consistent with previous studies of MeaB (Lofgren et al., 2013b) .
The switch II region is known to be important in binding to effector molecules (Herrmann, 2003) and indeed, the patient mutation p.Thr243Asn located in the switch II region caused loss of physical interaction.
There is no structural information to date on the physical interaction between MMAA and MUT. The recently determined crystal structure of bacterial IcmF, a fused protein consisting of MMAA-and MUT-like domains, suggests that residues 187-196 of MMAA may be important for physical interaction with MUT (Jost, Cracan, Hubbard, Banerjee, & Drennan, 2015) . Within this region, the mutant protein with the change of gly by arg at position 188 was unable to bind MUT in this and our previous study (Froese et al., 2010) . We superimposed the human MMAA and MUT structures onto IcmF to generate an approximate model of the MMAA-MUT complex, and found that a majority of mutations that abrogated MUT interaction/activation are found at the putative MMAA/MUT interface in our model (Supp. Fig. S7 ). Nevertheless, two mutations p.Gly192Asp and p.Arg196Gln that are also located in this interface did not strongly inhibit physical interaction between the two proteins. This is an indication that there are subtle differences in how MMAA and MUT interact, compared to the bacterial counterparts, that will only be resolved by future structural studies of the human complex.
We found factors affecting the interaction of MMAA and MUT, it was dependent on the presence of Mg 2+ and GMPPNP both in vitro and in vivo. Only the addition of Mg 2+ and GMPPNP to our immunoprecipitation led to detectable interaction. This suggests that, in the cell, the proteins form a very weak/transient interaction that can be stabilized in the presence of Mg 2+ and GTP. As in other G-proteins, the interaction of switch regions and the P-loop with phosphates and a coordinating Mg 2+ ion is essential for high affinity nucleotide binding (Vetter, & Wittinghofer, 2001) , which, for MMAA, might reflect the cellular prerequisites for MUT binding.
MMAB, responsible for catalysing the last step of AdoCbl assimilation, is also important for the direct transfer of AdoCbl to MUT (Padovani et al., 2008) . in all 15 mutants, the impairment in AdoCbl release is likely related to the decreased GTPase activity of MMAA mutants. This effect was even more significant for MMAA mutants unable to physically interact with MUT which also showed the lowest GTPase catalytic efficiency.
In addition to GTPase activity, the association of MUT and MMAA also plays a role in the gating of cofactor transfer from MMAB to MUT.
In conclusion, our investigation of novel patients and mutations in MMAA point to the importance of this protein within the context of its supporting role with MUT. This outcome is supported by the high proportion of truncating mutations and the loss of either protein stability or the ability to functionally interact with MUT in the case of missense mutations. These latter "loss of interaction" mutations are increasingly being found in the intracellular B 12 metabolic pathway, having already been identified in MMADHC, MMACHC (Froese et al., 2015) and MUT (Forny et al., 2014) . This further points to complexation as required for proper B 12 pathway function, and future studies will clarify the residues required for physical and functional interaction, as well as how MMAB, and perhaps MCEE (methylmalonyl-CoA epimerase), fit into this supramolecular multi-protein machinery.
